NMDA receptor blockade augmented nicotine-evoked dopamine release from rat prefrontal cortex slices

Neuroscience Letters

Volumn 440, Issue 3, 2008, Pages 319-322

  Rodvelt, Kelli R ^a   Schachtman, Todd R ^a   Kracke, George R ^b   Miller, Dennis K ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

Dopamine; Glutamate; Ketamine; Nicotine; NMDA; Schizophrenia

Indexed keywords

DOPAMINE; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINE RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; NICOTINE; NICOTINIC AGONISTS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TRITIUM;

EID: 45849114708     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.106     Document Type: Article

References (24)

1. Buccafusco J.J. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol. Interv. 4 (2004) 285-295
2. Carlsson A., Waters N., and Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 46 (1999) 1388-1395
3. Collins V.J., Gorospe C.A., and Rovenstine E.A. Intravenous nonbarbiturate, nonnarcotic analgesics: preliminary studies. 1. Cyclohexylamines. Anesth. Analg. 39 (1960) 302-306
4. Dani J.A., and Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 699-729
5. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
6. Duncan G.E., Miyamoto S., Leipzig J.N., and Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843 (1999) 171-183
7. Granon S., Poucet B., Thinus-Blanc C., Changeux J.P., and Vidal C. Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing. Psychopharmacology (Berl.) 119 (1995) 139-144
8. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27 (2007) 11496-11500
9. Jackson M.E., Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8467-8472
10. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
11. Kalman D., Morissette S.B., and George T.P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am. J. Addict. 14 (2005) 106-123
12. Kornhuber J., and Kornhuber M.E. Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci. 39 (1986) 699-774
13. Kosowski A.R., and Liljequist S. The NR2B-selective N-methyl-d-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-pipe ridine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens. J. Pharmacol. Exp. Ther. 311 (2004) 560-567
14. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994) 199-214
15. Levin E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53 (2002) 633-640
16. Mantz J., Varlet C., Lecharny J.B., Henzel D., Lenot P., and Desmonts J.M. Effects of volatile anesthetics, thiopental, and ketamine on spontaneous and depolarization-evoked dopamine release from striatal synaptosomes in the rat. Anesthesiology 80 (1994) 352-363
17. Rapier C., Lunt G.G., and Wonnacott S. Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J. Neurochem. 50 (1988) 1123-1130
18. Rodvelt, K.R., Kracke, G.R., Schachtman, T.R., Miller, D.K., Ketamine Induces Hyperactivity in Rats and Hypersensitivity to Nicotine in Rat Striatal Slices, Pharmacol. Biochem. Behav. (in press).
19. Shoaib M., Benwell M.E., Akbar M.T., Stolerman I.P., and Balfour D.J. Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. 111 (1994) 1073-1080
20. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry 133 (1976) 197-202
21. Takahata R., and Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J. Neurochem. 71 (1998) 1443-1449
22. Verma A., and Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16 (1996) 373-379
23. White P.F., Ham J., Way W.L., and Trevor A.J. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52 (1980) 231-239
24. Ziedonis D.M., Kosten T.R., Glazer W.M., and Frances R.J. Nicotine dependence and schizophrenia. Hosp. Community Psychiatry 45 (1994) 204-206